Podcast artwork thumbnail for Biotech Hangout

Biotech Hangout

Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler

Booking Overview

A weekly panel show focused on biotechnology market news, clinical data, dealmaking, and FDA actions, with external biotech executives and industry experts appearing alongside recurring panelists. PR agencies could credibly pitch biotech CEOs, pharmaceutical executives, drug-development leaders, regulatory specialists, and experienced biotech investors or analysts; booking difficulty is medium because guests generally need substantial industry expertise or senior leadership credentials.

Metrics

Episodes: 167

Frequency: Weekly

Rating: 4.5/5.0

Estimated listeners: 100 - 1,000

Gender skew: Male

Listener location: USA

YouTube: 247 subscribers

Contact Information

Publicly listed emails

team@biotechhangout.com

Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.

Host

Daphne Zohar - Founder and chief executive officer of PureTech Health, focused on developing and commercializing biotechnology and healthcare innovations.

Josh Schimmer - Biotechnology equity research analyst and managing director at Evercore ISI, specializing in biotech companies, therapeutics, and industry developments.

Brad Loncar - Biotechnology investor and chief executive officer of Loncar Investments, known for investment strategies focused on biotech and healthcare companies.

Tim Opler - Investment banker and biotechnology industry commentator with expertise in healthcare companies, financing, and dealmaking.

Booking Intelligence

Booking Requirements

medium
Typical Credentials:  
Biotechnology or pharmaceutical executives, drug-development leaders, healthcare investors and analysts, or specialists with substantial expertise in clinical trials, regulation, financing, or biotech strategy.
Required Achievements:  
Led a biotechnology or pharmaceutical company, Advanced a drug-development or clinical-stage program, Built expertise in biotech investing, equity research, or dealmaking, Played a senior role in healthcare financing, regulation, or commercialization

Recent Guest Discussions

Jake Becraft - Biotech Dealmaking, Ipos And Reverse Mergers, China Biotech, FDA Designations, Oncology Development, And The Pharmaceutical Market.

Recent Topics

Biotechnology, Drug Development, Pharmaceuticals, Fda, Biotech Investing

Episodes

Here's the recent few episodes on
Biotech Hangout
:

Episode 198 - October 2, 2026

October 02, 2026

On this week's episode, Graig Suvannavejh, Sam Fazeli, Eric Schmidt, and Brian Skorney open with a look at the public markets, noting the XBI is up 27% year-to-date but down about 9% since its August high. The co-hosts then touched on Oura's pulled IPO, seeing little read-through for the broader biotech space. In deals, Sanofi and Regeneron extended their antibody collaboration for $1 billion upfront and up to $7 billion in milestones, while AstraZeneca and Daiichi Sankyo struck deals...

Episode 197 - September 25, 2026

September 25, 2026

On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group turns to policy, unpacking newly FOIA-disclosed details of Pfizer's MFN agreement, including a revenue-share provision tied to price increases abroad. The co-hosts call the equalization concept constructive but warn cash-strapped European governments may ration access rather than pay more. They also discuss FDA commi...

Episode 196 - September 18, 2026

September 25, 2026

On this week's episode, Josh Schimmer, Eric Schmidt, Paul Matteis, and guest Adam Feuerstein open with the OpenAI/Hugging Face AI agent controversy, debating whether calls for AI regulation reflect genuine safety concern or capital rotating out of biotech into AI. Turning to markets, the group describes a choppy September for biotech, driven more by rate jitters and a quiet M&A backdrop than any real shift in FDA or drug-pricing sentiment. In data news, Xenon Pharmaceuticals voluntari...

Frequently asked questions

Here's some frequently asked questions for
Biotech Hangout
:

How do I get in touch with Biotech Hangout?

Biotech Hangout is hosted by Daphne Zohar and Josh Schimmer. Its publicly listed email is team@biotechhangout.com. For guest bookings, the host or producer is usually the best person to reach. Podseeker helps you find direct host and producer contacts and pitch from your own inbox.

What is the email for Biotech Hangout?

The publicly listed email for Biotech Hangout: team@biotechhangout.com.

How many listeners does Biotech Hangout have?

Podseeker estimates Biotech Hangout reaches 100 to 1,000 listeners per episode. Only the publisher has exact numbers.

Who is an ideal guest for Biotech Hangout?

Biotech Hangout typically books industry leaders. Typical guest background: Biotechnology or pharmaceutical executives, drug-development leaders, healthcare investors and analysts, or specialists with substantial expertise in clinical trials, regulation, financing, or biotech strategy. Common among recent guests: Led a biotechnology or pharmaceutical company; Advanced a drug-development or clinical-stage program; Built expertise in biotech investing, equity research, or dealmaking. Recent guests include Jake Becraft.

How hard is it to get booked on Biotech Hangout?

Medium. Guests usually need solid credentials in the topic and an idea that fits the show.

What topics does Biotech Hangout cover?

Recent episodes cover Biotechnology, Drug Development, Pharmaceuticals, Fda, and Biotech Investing. Pitch an idea tied to one of these topics and mention a recent episode.

Publicly listed emails

team@biotechhangout.com

Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.

Get your clients booked on top podcasts

Try us risk free with a FREE 3 days trial.

Start Your Free Trial

Join hundreds of PR teams using Podseeker to pitch and land bookings